Home / World / Illumina Issues a Warning, Colgate-Palmolive Makes an Acquisition

Illumina Issues a Warning, Colgate-Palmolive Makes an Acquisition



Tonight is shaping up to be a nighttime session and, for some, lucrative, for nighttime merchants. There is some interesting news to digest and, as a result, at least some actions in motion.

What companies are these? Read on to find out.

A hand with tweezers that extracts a section of a large strand of DNA. Piece of a DNA strand model.

Image source: Getty Images.

Illumina cuts its orientation throughout the year.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Actions of the DNA sequencing company Illumina (NASDAQ: ILMN) They're really taking it in the chin tonight. After the market closed, the company noted that its quarterly revenues will not meet expectations. He also cut his first-line 2019 tax guide. "Data-reactid =" 26 "> Actions of the DNA sequencing company Illumina (NASDAQ: ILMN) They're really taking it in the chin tonight. After the market closed, the company noted that its quarterly revenues will not meet expectations. It also cut its fiscal orientation from the top line of 2019.

Illumina said its preliminary figures show it will reserve $ 835 million for its Q2, a $ 50 million shave of its expectations, although still higher than the $ 830 million Q2 2018. For the entire fiscal year 2019, the company believes that its top line will reach 6% more than the result of $ 3.3 billion in 2018; Previously anticipated growth from 13% to 14%.

In the press release that transmits the bad news, Illumina said that the result of the second quarter revenues, lower than expected, is mainly due to sales that were not made as anticipated in the genomics segment of the population. He also pointed out the "continuous weakness" with his direct efforts to the consumer (DTC), among other factors.

The company tried to make an optimistic note despite the setback, and wrote that "our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business."

It does not seem that investors are taking the word of the company. Illumina shares have dropped 16% tonight from the market closing price.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The timing of this announcement is not ideal for the actions. Recently it had been negotiating at its highest point of all time, based on positive foundations and anticipated advance in its imminent acquisition of Biosciences of the Pacific. & nbsp; "data-reactid =" 31 "> The timing of this announcement is not ideal for the action, it has recently been negotiating at its highest point of all time, based on the positive foundations and the anticipated progress in its imminent acquisition of Biosciences of the Pacific.

Purchase $ 1.7 billion Colgate-Palmolive

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Giant consumer goods Colgate-Palmolive (NYSE: CL) Soon it will be a bigger asset. The company announced that it has reached an agreement to buy the skin care business of Laboratoires Filorga Cosmetiques de Francia. "Data-reactid =" 33 "> Giant consumer goods Colgate-Palmolive (NYSE: CL) Soon it will be a bigger asset. The company announced that it had reached an agreement to buy the skin care business of Laboratoires Filorga Cosmetiques de Francia.

Colgate-Palmolive will pay 1,500 million euros ($ 1,700 million) for the business. It will finance this through a combination of cash and debt.

Filorga manufactures a line of high-end anti-aging skin care products. It has a global presence, and is particularly strong in European countries such as its native France and Italy. It is also prominent in China.

The acquisition is part of Colgate-Palmolive's efforts to strengthen its presence in comparatively high-margin segments, such as pet nutrition and personal care.

"We are excited that this acquisition will add a high-growth, profitable and global asset for skin care to the Colgate portfolio with the opportunity to drive continued growth through greater distribution and knowledge," Colgate said. press release announcing the agreement.

The acquisition of Filorga is subject to the approval of the relevant regulatory bodies. Colgate-Palmolive expects it to close in Q3. The company said it probably would not have any impact on the profitability of fiscal year 2019.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "It may not have much impact on the investor sentiment, since be (although on the back of some good recent results, this has been quite positive this year). In the post-market action, Colgate-Palmolive shares are down, but only marginally. "Data-reactid =" 39 "> It may not have a big impact on investor confidence either (although in light of some good recent results, this has been very positive this year). Colgate-Palmolive shares have declined, but only marginally.

New CEO at Accenture

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Accenture (NYSE: ACN) It was announced after the market closed today that it has selected a new leader. "data-reactid =" 45 ">Accenture (NYSE: ACN) It was announced after the market close today that you have selected a new leader.

The big consultant is selecting the company's expert, Julie Sweet, to be its new CEO, replacing interim CEO David Rowland. Sweet will begin his term on September 1, at which time he will also take a seat on the board of directors. Rowland will become CEO at that time.

Sweet has been with Accenture since 2010. She is currently the executive director of the company's North America division, its most important region. Previously, she served as general counsel of the company, director of compliance and secretary.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The veteran of the company seems to be a solid option to fill the CEO's seat Accenture's operations in North America registered sales growth of 9%. in the last quarter reported, surpassing the figures of other important regions. Meanwhile, the company as a whole has delivered encouraging improvements in both the top line and the bottom line recently. & Nbsp; "data-reactid =" 48 "> The veteran of the company seems to be a solid option to fill the CEO's position Accenture's operations in North America recorded sales growth of 9% in the last quarter reported, surpassing the figures from other important regions, while the company as a whole has achieved encouraging improvements in both the top line and the bottom line.

Accenture shares have risen slightly in post-close operations tonight.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " More from The Motley Fool "data-reactid =" 50 "> More from The Motley Fool

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Eric Volkman It has no position in any of the actions mentioned. The Motley Fool owns shares and recommends Illumina. The Motley Fool is short stock of Colgate-Palmolive. Motley Fool recommends Accenture. The Motley Fool has a disclosure policy."data-reactid =" 58 ">Eric Volkman has no position in any of the actions mentioned. The Motley Fool owns shares and recommends Illumina. The Motley Fool is short stock of Colgate-Palmolive. Motley Fool recommends Accenture. The Motley Fool has a disclosure policy.


Source link